BBIO - LianBio files sets terms for $325M initial public offering

LianBio, which has clinical candidates in several therapeutic areas, has set terms for its $325M initial public offering. The offering is for 20,312,500 American Depository Receipts representing 20,312,500 ordinary shares with the share price between $15 and $17. The company has applied to list on Nasdaq under the symbol "LIAN" (LIAN). LianBio has two candidates in phase 3. Infigratinib (BGJ398) is in partnership with BridgeBio Pharma (NASDAQ:BBIO) for first- and second-line cholangiocarcinoma. TP-03 is in partnership with Tarsus Pharmaceuticals (NASDAQ:TARS) for demodex blepharitis. In China, LianBio plans on initiating a phase 3 bridging and PK study for mavacamten for obstructive hypertrophic cardiomyopathy. The company is partnered with Bristol-Myers Squibb on the candidate.

For further details see:

LianBio files sets terms for $325M initial public offering